Akums Drugs & Pharmaceuticals' Q3 FY 2025-26 Quarterly Results
- 14 Feb 2026
Result Summary
- Akums Drugs & Pharmaceuticals Ltd reported a 13.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 16.5%.
- Its expenses for the quarter were up by 9.3% QoQ and 14.6% YoY.
- The net profit increased 58.5% QoQ and increased 2.1% YoY.
- The earnings per share (EPS) of Akums Drugs & Pharmaceuticals Ltd stood at 4.33 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 1193.92 | 1049.90 | 1024.97 | 13.7% | 16.5% |
Total Expenses | 1076.12 | 984.21 | 938.70 | 9.3% | 14.6% |
Profit Before Tax | 99.57 | 65.67 | 91.05 | 51.6% | 9.4% |
Tax | 31.89 | 22.98 | 24.74 | 38.8% | 28.9% |
Profit After Tax | 67.68 | 42.69 | 66.31 | 58.5% | 2.1% |
Earnings Per Share | 4.33 | 2.66 | 4.26 | 62.8% | 1.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Akums Drugs & Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry. The company specializes in manufacturing and supplying a wide range of pharmaceutical formulations. Akums is known for its comprehensive services, including product development, manufacturing, and regulatory support, catering to various segments such as tablets, capsules, injectables, and more. The company has established itself as a reliable partner for pharmaceutical brands in India and internationally. While the provided data does not include recent major developments, Akums continues to focus on innovation and quality compliance to maintain its competitive edge in the industry.
Revenue
In Q3FY26, Akums Drugs & Pharmaceuticals Ltd reported a total income of ₹1193.92 crores, marking a significant increase of 13.7% compared to the previous quarter (Q2FY26) where the total income was ₹1049.90 crores. On a year-over-year basis, there was a 16.5% increase from Q3FY25, where the total income stood at ₹1024.97 crores. These figures indicate a steady growth trajectory in the company's revenue generation capabilities over both the quarterly and annual periods.
Profitability
The profitability of Akums Drugs & Pharmaceuticals Ltd showed positive growth in Q3FY26. The profit before tax was reported at ₹99.57 crores, reflecting a notable 51.6% increase quarter-over-quarter from ₹65.67 crores in Q2FY26. Year-over-year, there was a 9.4% increase from ₹91.05 crores in Q3FY25. The profit after tax for Q3FY26 was ₹67.68 crores, which represented a 58.5% rise from Q2FY26's ₹42.69 crores and a slight increase of 2.1% from Q3FY25's ₹66.31 crores. The earnings per share also increased significantly, from ₹2.66 in Q2FY26 to ₹4.33 in Q3FY26, marking a 62.8% QoQ growth and a 1.6% YoY growth from ₹4.26 in Q3FY25.
Operating Metrics
The total expenses for Akums Drugs & Pharmaceuticals Ltd in Q3FY26 were ₹1076.12 crores, showing an increase of 9.3% from ₹984.21 crores in Q2FY26, and a 14.6% increase from ₹938.70 crores in Q3FY25. The tax expense for the quarter was ₹31.89 crores, up by 38.8% from Q2FY26's ₹22.98 crores and a 28.9% increase from ₹24.74 crores in Q3FY25. These operating metrics highlight the company's expenditure and tax obligations, which have increased in line with the growth in income and profitability. The increase in these expenses indicates a proportional adjustment to the company's operational scale.